A community pharmacist medicines optimisation service for patients with advanced cancer pain: a proof of concept study by Edwards, Zoe et al.
Vol:.(1234567890)
International Journal of Clinical Pharmacy (2019) 41:700–710
https://doi.org/10.1007/s11096-019-00820-8
1 3
RESEARCH ARTICLE
A community pharmacist medicines optimisation service for patients 
with advanced cancer pain: a proof of concept study
Zoe Edwards1  · Michael I. Bennett2 · Alison Blenkinsopp1
Received: 22 November 2018 / Accepted: 28 March 2019 / Published online: 9 April 2019 
© The Author(s) 2019
Abstract
Background Patients with advanced cancer commonly experience pain and it is least controlled in community settings. 
Community pharmacists in the UK already offer medicines optimisation consultations although not for this patient group. 
Objective To determine whether medicines consultations for patients with advanced cancer pain are feasible and acceptable. 
Setting Community-dwelling patients with advanced cancer pain were recruited from primary, secondary and tertiary care 
using purposive sampling in one UK city. Methods One face-to-face or two telephone delivered medicines optimisation 
consultations by pharmacists were tested. These were based on services currently delivered in UK community pharmacies. 
Feedback was obtained from patients and healthcare professionals involved to assess feasibility and acceptability. Main 
outcome measure Recruitment, acceptability and drug related problems. Results Twenty-three patients, (range 33–88 years) 
were recruited, 19 completed consultation(s) of whom 17 were receiving palliative care services. Five received face-to-face 
consultations and 14 by telephone during which 47 drug related problems were identified from 33 consultations (mean 2.5). 
Advice was provided for 34 drug related problems in 17 patients and referral to other healthcare professionals for 13 in 8 
patients, 2 patients had none. Eleven patients returned questionnaires of which 8 (73%) would recommend the consultations 
to others. Conclusion The consultations were feasible as patients were recruited, retained, consultations delivered, and data 
collected. Patients found the 20–30 min intervention acceptable, found a self-perceived increase in medicines knowledge 
and most would recommend it to others. Community pharmacists were willing to carry out these services however they had 
confidence issues in accessing working knowledge. Most drug related problems were resolved by the pharmacists and even 
among patients receiving palliative care services there were still issues concerning analgesic management. Pharmacist-
conducted medicines consultations demonstrate potential which now needs to be evaluated within a larger study in the future.
Keywords Cancer · Community pharmacy · Medicines optimisation · Pain · Palliative care · Remote consultation · United 
Kingdom
Impacts on practice
• Pharmacist-delivered medicines consultations are feasi-
ble and acceptable to cancer patients and have the poten-
tial to benefit clinical care.
• Even for patients under specialist palliative care services, 
unmet medicines-related needs can be identified by phar-
macists.
• Access to pharmacist care for patients with advanced 
cancer who are not able to visit the pharmacy in per-
son should be improved.
Introduction
Over half of patients with advanced cancer will experience 
poorly controlled pain during their last year of life [1, 2]. 
Only 18% of patients at the end-of-life living in the com-
munity describe their pain as well controlled compared with 
38% of patients in hospitals and 63% of patients in hospices 
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[3]. Often, community-based patients feel they lack support 
with their medicines taking and accept experiencing pain [4].
Community Pharmacists are the healthcare professional 
seen most frequently by patients with cancer (along with 
community nurses) [5] and are often available in every local-
ity without an appointment. Community pharmacies may be 
in or near family doctor practices or sometimes in shopping 
centres or supermarkets and could potentially be an accessi-
ble source of medicines support for patients with cancer pain. 
Medicines optimisation services are provided by community 
pharmacists in the UK, USA, Australia and New Zealand 
with the aim of helping patients get the most benefit possible 
from the medicines they have been prescribed [6–10]. In the 
UK the two most common are detailed in Table 1.
The World Health Organization Pain ladder provides 
stepwise guidance for adult pain management [11]. Severe 
pain can usually be controlled by regular dosing of simple 
pain killers, adjuncts and sustained-release pain medication 
with top-up or breakthrough doses in-between but patients 
need to understand their medicines to gain optimum benefit 
from them [12, 13]. Pharmacist medicines consultations 
have been shown to increase patient knowledge and have 
associated improvements in medicines adherence [14, 15].
Although community pharmacist medicines consultations 
are rarely carried out with patients experiencing cancer pain, 
several studies have investigated the contributions they could 
make [16–19]. Outcome measures included the quantity of 
Drug Related Problems (DRPs), recommendations made and 
an assessment of the appropriateness of recommendations 
[16–20]. A DRP can be defined as an event or circumstance 
involving drug therapy that actually or potentially interferes 
with desired health outcomes [21]. Patient’s perspectives 
are often difficult to obtain post-intervention from patients 
with advanced disease due to rapid deterioration and only 
one study included this [18, 22]. A recent systematic review 
showed that pharmacist educational interventions are poten-
tially beneficial for patients with cancer pain but further 
research is needed in this area [23].
Lack of pharmacist confidence to provide services for 
patients with cancer has been identified as a barrier to ser-
vice provision [24–26]. All previous studies either employed 
a specialist palliative care pharmacist or provided some sort 
of additional training, although the content and evidence-
base of training was not always reported [16–19].
Aim
To evaluate pharmacist medicines consultations for patients 
with advanced cancer and to ascertain their feasibility and 
acceptability.
Ethics approval Ethical permission was granted from Leeds 
West National Health Service and Bradford University Ethi-
cal Committee in October 2014 (14-YH-1126 141015). This 
study was part of the larger Improving the Management of 
Pain from Advanced Cancer in the Community (IMPACCT) 
study.
Method
Recruitment site identification
Research ready family doctor practices with practice phar-
macists1 were identified and approached. Recruitment com-
menced in November 2015 and continued until March 2017.
The recruitment process was iterative responding to the 
levels of identification and recruitment of patients. New and 
refined recruitment methods were developed, and the local 
Table 1  Medicines optimisation services provided by community pharmacies in England and Wales
Service Medicine use review (MUR) New medicine service (NMS)
Which patients? 70% must be targeted towards specified patient disease 
groups (not including cancer). The remainder may be 
carried out with any other patient [9]. They must be 
carried out in the patients usual community pharmacy 
[9]
Patients prescribed new medicines for specified long-
term conditions [10]
Method of delivery One consultation, usually face-to-face but telephone 
possible with relevant permissions [9]
Patient can choose face to face or telephone delivery. Up 
to three consultations: Initial advice, intervention and 
follow-up consultations usually by telephone [10]
Use in patients with cancer Research indicates rarely provided [11] Cancer not one of the specified long-term conditions 
[10]
Reimbursement £28 [9] Between £20 and £28 depending on number provided 
[10]
1 Practice pharmacist refers to a role within family doctor or General 
Practitioner (GP) practices which aids with prescribing, audit, costing 
and sometimes performing clinical roles. They were involved in this 
study to allow electronic records to be checked to identify patients 
and assess eligibility criteria.
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hospital and hospice were invited to be recruitment sites 
towards the end of the study.
Community pharmacist recruitment
The 10 pharmacies closest to the practices recruited were 
identified (four from national multiples and six independ-
ents) and contact was made with owners or head offices. 
Nine agreed to take part with one independent stating lack 
of interest. An interactive briefing session for the pharma-
cists was developed based on the specific needs of com-
munity pharmacists found in previous studies [24–26]. 
Information from a specialist nurse and a cancer support 
charity was delivered and role plays were carried out with 
a cancer survivor from our Patient and Public Involvement 
(PPI) group. Pharmacists and support staff representing all 
community pharmacies attended the training which was 
well received.
Patients who used one of the study pharmacies were 
offered either a telephone-based Medicine Use Review 
(MUR) or a face-to-face MUR (see Table 1).
Patients who did not use one of the study pharmacies 
were offered telephone consultations from the Research 
Pharmacist (RP) using the New Medicine Service (NMS) 
format allowing the same issues to be discussed over a series 
of two telephone consultations (see Table 1). Our earlier 
research showed that patients with advanced cancer were 
willing to try this [4].
Patient recruitment
In family doctor practices, searches using the study inclu-
sion criteria (see Box 1) were conducted in electronic sys-
tems by practice pharmacists. Community pharmacists, 
district nurses and family doctors were asked to refer suit-
able patients to the GP practice, where the practice phar-
macist screened them and confirmed suitability with their 
GP. Oncology research nurses at the local hospital were 
asked to conduct outpatient clinical records searches. The 
hospital outpatient pharmacy was asked to refer patients 
to the research nurses. Patients from primary and sec-
ondary care recruitment were then invited to take part 
by letter.
The hospice research nurse, together with the study RP 
undertook recruitment in the local hospice. Patients about to 
be discharged or attending outpatient clinics were introduced 
to the study by their nurse. Those who expressed interest 
were provided with written information and consented face-
to-face by the RP.
All patients gave written consent.
Sample
As this was a proof-of-concept study a formal sample size 
was not required but we aimed to recruit 25 patients as this 
was adequate to assess whether it was possible to recruit 
and retain patients, whether the consultations were deliv-
erable and acceptable to patients and healthcare profes-
sionals involved.
Medicines optimisation consultations
The length of each consultation was noted by the pharma-
cist and any recommendations made to the patient and/
or the prescriber were documented contemporaneously, in 
line with usual practice for NMS and MUR. Consultation 
records used a study code and did not contain any patient 
identifiable information.
Patient and pharmacist feedback
Baseline and post-consultation follow-up patient question-
naires were developed based on validated pain measure-
ment tools used in the IMPACCT study [27, 28]. Drafts 
were piloted with the study PPI group and feedback was 
Box 1  Recruitment criteria
a Patients with advanced cancer are defined as those with metastatic cancer with histological, cytological or radiological evidence AND/OR those 
receiving anti-cancer therapy with palliative intent
b Opioids are codeine, codeine and paracetamol, codeine and ibuprofen, dihydrocodeine, paracetamol and hydrocodeine, tramadol, tapentadol, 
morphine, fentanyl, buprenorphine, diamorphine, hydromorphone, methadone and oxycodone
c Anticipatory medicines are medicines which are often used to control symptoms in the last days of life. These are usually prescribed in a pack-
age as this time approaches
1. Aged over 16 years old
2. Have advanced  cancera, are aware of their diagnosis and are suffering from pain
3. Been given a prescription for  opioidsb
4. Have not been prescribed anticipatory  medicinesc and are therefore not in the last days of life
5. Have the capacity to provide informed consent and complete questionnaires before and after the consultation
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obtained. The questionnaire included quantitative and 
qualitative questions about levels of pain (worst experi-
enced in the last 24 h and at time of questionnaire com-
pletion on a 0–10 scale (0 = no pain to 10 = pain as bad as 
they could imagine). Self-reported knowledge information 
was also collected. The baseline questionnaire was posted 
before the consultation with a stamped addressed return 
envelope. The follow-up questionnaire was sent 2 weeks 
after the final consultation and included additional ques-
tions on self-perceived benefit from the consultation and 
whether the patient would recommend the medicines con-
sultation to others. Questionnaires are available on request 
from the author.
Data analysis
Medicines consultation records were coded by the RP using 
the Pharmaceutical Care Network Europe (PCNE) classifi-
cation which is a validated system developed by experts to 
document DRPs, their cause and action taken following their 
identification [21].
Information from the baseline and follow-up question-
naires was collated and analysed using Excel spreadsheets.
Feasibility
This will be assessed by whether it was possible to recruit 
and retain patients throughout the study and whether it 
was possible to train community pharmacists to deliver 
consultations.
Acceptability
A theoretical framework which was developed based on sys-
tematic reviews involving acceptability and inductive and 
deductive reasoning of reviews and literature is available 
[29]. The framework details acceptability before (prospec-
tive), during (concurrent) and after the intervention (retro-
spective). This was adapted to assess acceptability of the 
intervention. Three questions requiring likert responses were 
included in the questionnaires as a result:
1. I feel I benefitted from the consultation.
2. I was able to ask all the questions I wanted to.
3. I would recommend a pharmacist pain medicines con-
sultation to other people.
Data was also collected on whether the community 
pharmacists completed the consultations when they were 
requested to do so. The day after the scheduled consultation, 
the RP telephoned the community pharmacist and gathered 
unstructured feedback about the experience of providing the 
consultation.
Results
128 patients were identified for the study; 47 were confirmed 
as eligible by their healthcare professional and invited to 
take part. Twenty-three consented to participate and 19 
received the medicines consultations of whom 17 were 
already receiving specialist palliative care services.2 Four 
patients deteriorated or died before they had consultations. 
Patients were aged between 33 and 88 (average 64 years 
old). More detail about recruitment methods is available 
elsewhere [30].
Four community pharmacists were requested to deliver 
five consultations, of which all took place. Five patients had 
a face-to-face MUR from four different community pharma-
cists (3 independents and 1 multiple) and 14 had two NMS-
type consultations from the RP. Five patients were una-
vailable at the second telephone consultation and required 
further phone calls. One patient had hearing difficulties and 
asked for his spouse to be involved in the telephone call to 
aid communication.
The mean duration of medicines consultations was 
31 min for MUR (range 20–60 min) and for the NMS type 
consultations the mean total time for the two consultations 
was 18 min (range 9–29 min) per patient.
In total 47 DRPs were identified in 17 patients with a 
mean of 2.5 per patient (range 0–7, median 2) (see Table 2). 
Consultations were often multi-faceted (see Exemplar case 
studies-Box 2) and MURs averaged 1.2 DRPs per patient 
and the NMS-type averaged 3. Advice was given to 17 
patients to resolve 34 DRPs and 13 (for 8 patients) were 
addressed by referral to other healthcare professionals: 6 to 
recommend prescribing of additional medication (for pain, 
constipation or dry mouth), 2 for a concomitant medicines 
query, 2 to recommend an alternative medicine (for consti-
pation), 1 for an alternative dosage form and 2 to flag up 
important symptoms to the prescriber.
Full details of the PCNE classification can be found in 
“Appendix 1” [21].
Feedback from patients
Eleven patients returned both baseline and post-consulta-
tion questionnaires. The answers to the three acceptability 
2 Specialist Palliative Care Services are received by patients who 
have been referred and usually involves access to multidisciplinary 
palliative care healthcare professionals to provide symptom control.
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Table 2  Medicine related problems and how they were addressed (n = 19)
Patient Were they receiving spe-
cialist palliative care?
No of MRPs 
identified
MRP details PCNE problem PCNE cause PCNE inter-vention
Ph8X1 Unknown 2 Advice P3.3 C5.2 I2.1
Advice P3.3 C5.2 I2.1
Ph4X1 Y 2 Pain—paracetamol P1.2 C7.1 I2.1
Constipation P1.3 C1.6 I2.1
Ph8X2 Y 0 – – – –
Ph10X1 N 0 – – – –
Ph9X1 Y 2 Adjuvant dosage P1.2 C5.2 I2.1
Constipationa P1.3 C1.6 I1.3
MC5 Y 3 Pain P1.1 C3.5 I2.1
Compliance P1.2 C7.1 I2.1
Advice P3.3 C5.2 I2.1
MC6 Y 3 Pain—ibuprofen P1.2 C7.1 I2.1
Pain—paracetamol P1.2 C7.1 I2.1
Breathlessness P1.3 C5.2 I2.1
MC7 Y 3 Compliance P1.2 C7.7 I2.1
Pain—paracetamola P1.2 C1.6 I1.4
Other  medicationa P1.3 C7.1 I1.4
MC8 Y 2 Drug  forma P1.2 C2.1 I1.3
Side effects P2.1 C5.2 I2.1
MC9 Y 2 Pain—Paracetamol P1.2 C7.1 I2.1
Side effects P2.1 C5.2 I2.1
MC10 N 2 Pain—paracetamol P1.2 C7.1 I2.1
Compliance P1.2 C7.1 I2.1
MC11 Y 1 Constipation P1.2 C7.1 I2.1
MC12 Y 5 Pain P1.2 C7.7 I2.1
Side effect P2.1 C5.2 I2.1
Constipation P1.2 C7.1 I2.1
Side effect P2.1 C5.2 I2.1
MC13 Y 3 Paina P1.2 C3.1 I1.3
Laxativea P1.2 C3.1 I1.4
Advice P3.3 C5.2 I2.1
MC14 Y 1 Other medication P1.2 C7.7 I2.1
BRI1 Y 3 Pain P1.2 C7.1 I2.1
Constipationa P1.3 C1.6 I1.3
Medicines sourcing P3.3 C5.2 I2.1
Side  effecta P2.1 C5.2 I2.1
MC15 Y 2 Pain P1.2 C7.1 I2.1
Other medication  issuesa P3.2 C1.5 (I1.4, I3.5)
MC16 Y 5 Pain—morphine P1.2 C7.1 I2.1
Pain—paracetamol P1.2 C7.1 I2.1
Constipation P1.2 C7.1 I2.1
Side  effectsa P1.3 C1.6 I1.4
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Table 3  Participants’ baseline and follow-up questionnaire responses including acceptability data (n = 11)
Unknown is stated where questionnaires were not returned
Pre-intervention 
average pain 
score (0–10)
Post-intervention 
average pain 
score (0–10)
Pre-intervention 
“Do I know 
enough about my 
medicines?”
Post interven-
tion “Do I know 
enough about my 
medicines?”
I feel I benefited 
from the consul-
tation?
I was able to ask 
all the questions 
I wanted to?”
I would recom-
mend a pharmacist 
pain medicines 
consultation to 
other people?
Ph8X2 0.5 6.0 Don’t know Yes Agree Agree Agree
Ph10X1 0.0 0.0 Yes Not answered Strongly agree Strongly agree Strongly agree
Ph9X1 6.5 7.5 No No Neutral Agree neutral
MC6 2.0 1.5 Don’t know Yes Neutral Agree neutral
MC7 3.0 3.5 No No Disagree Not answered Not answered
MC9 4.0 7.0 Yes Yes Agree Strongly agree Strongly agree
MC10 4.0 2.5 Yes Yes Agree Agree Agree
MC11 3.5 1.5 No No Neutral Agree Agree
MC14 6.0 6.0 No Yes Strongly agree Strongly agree Strongly agree
MC15 3.0 3.5 No Yes Strongly agree Strongly agree Strongly agree
MC16 5.0 4.5 No Yes Agree Agree Agree
Box 2  Exemplar patient case studies
Case 1
Patient MC13 who was taking multiple medicines, was discharged from the hospice after several weeks of symptom control. The patient 
received the NMS style intervention but felt that it would have been more useful before their inpatient stay.
At consultation 1 the patient only had a few questions about their medication.
At consultation 2 (2 weeks later) their pain had changed, they were struggling with control, using seven top-up doses of strong opioid each 
day and severely constipated. The patient reported struggling psychologically with others’ perceptions of their pain. Other issues discussed 
included getting the best use from currently prescribed medicines. A referral was made to the patient’s usual healthcare professional for a 
suggested increase in slow-release strong opioid and a change in constipation medication. The pharmacist was asked by the healthcare profes-
sional to recommend medication for constipation and to investigate its availability.
Case 2
When patient MC5 was contacted for the first NMS-style consultation they were in severe pain and had not been taking their medication as 
they were in “too much pain” with the pain affecting their ability to think, sleep and function. Paracetamol and tramadol had been prescribed 
but the patient was not taking paracetamol as they thought their condition was beyond that. The pharmacist explained about taking pain 
medication on a regular basis and how this could prevent large spikes in pain, and that the effects of paracetamol could make a difference. 
The patient was concerned about transitioning to strong opioid medication in the future and the associated risk of addiction. This was dis-
cussed at length. At the second consultation 9 days later, the patient had started taking more regular pain relief, including a new prescription 
for morphine sulphate liquid and reported great improvement.
Table 2  (continued)
a Indicates MRPs which were referred to another healthcare professional
Patient Were they receiving spe-
cialist palliative care?
No of MRPs 
identified
MRP details PCNE problem PCNE cause PCNE inter-vention
MC17 Y 7 Paina P1.3 C1.6 I1.3
Paina P1.3 C1.6 I1.3
Advice P3.3 C5.2 I2.1
Side effects P1.2 C5.2 I2.1
Advice P3.3 C5.2 I2.1
Constipation P1.2 C7.1 I2.1
Constipationa P1.2 C1.6 I1.4
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questions are shown in Table 3 along with other questions 
regarding pain and self-reported knowledge. 
Pre-consultations, the mean pain score was 4.1 (range 
0–8) and three patients felt they knew enough about their 
medicines compared with 4.0 and seven at follow-up. No 
other medicines education support was reported by patients 
during the intervention period.
Feedback from community pharmacists
At the follow-up phone call after the consultations three of 
the four community pharmacists reported having some chal-
lenges in carrying out the consultations. Two reported lack 
of confidence and three had difficulties in retaining knowl-
edge when the consultations were so infrequent.
Difficulties with recruitment
Several methods of recruitment were used of which one 
(hospice) produced 18 of the 23 participants. Face to 
face recruitment methods were found to be more effec-
tive than by letter and recruitment was more successful 
where healthcare professionals were engaged in the study. 
Full details and evaluation of methods used are reported 
elsewhere [30]. 
Discussion
This study shows that even for patients receiving specialist 
palliative care, pharmacist-delivered medicines consulta-
tions were feasible and acceptable to patients and had the 
potential to benefit clinical care.
Feasibility
We found that identification of patients was more difficult 
than expected so additional methods were developed itera-
tively. Recruitment and attrition rates were in line with 
other similar studies [31, 32].
Community pharmacists found it difficult to retain 
working knowledge regarding cancer and this could poten-
tially be improved if the consultations were carried out 
more frequently. Creation of referral pathways to com-
munity pharmacy were not successful, therefore we also 
tested telephone provision of medicines consultations by 
one centralised RP. This was used successfully with a 
broad age range of patients.
We know from previous research that one in three 
patients are never referred to specialist palliative care 
services and we hypothesise that these patients may have 
greater need for a medicines consultation [4, 33]. Recruit-
ment methods used were less successful in finding those 
who had not been referred to palliative care. Even though 
almost all our participants were receiving this; a mean of 
2.5 DRPs per patient was found showing a need for extra 
support even in this group.
Acceptability to patients
All patients who had an NMS-type service (n = 14) agreed 
to the second consultation after having the first so we 
deduce that patients found them acceptable.
The majority of consultations were carried out via tel-
ephone. This method was acceptable for all patients who 
received it and some studies show this may even be pref-
erable for some, especially those who are seriously ill [4, 
34]. Telephone-based appointments are already used in 
many community pharmacies and family doctor practices 
with high levels of patient satisfaction [35–37].
Retrospective acceptability can be estimated by per-
ceived effectiveness and self-efficacy. Most patients felt 
they benefitted from the consultations (which was also 
found elsewhere), were able to ask all the questions they 
wanted to and would recommend it to others [35]. There 
was an increase in patients who felt they knew enough 
about their medicines following the intervention indicating 
that knowledge was increased. Pain levels in this patient 
group can change rapidly due to the nature of the illness 
although average pain levels remained the same [22]. This 
may be due to a negation in the expected deterioration over 
time although on such a small sample it is difficult to draw 
any such conclusions. Patient evaluation is more likely to 
be obtained following a one-off intervention so this may 
have affected our response rates [38].
Acceptability to healthcare professionals
One community pharmacy (n = 10) declined to be involved 
but all 9 who agreed sent representatives to the voluntary 
training showing prospective acceptability was generally 
good. There were a mix of independent and multiple com-
munity pharmacies showing a willingness of both groups 
to take part.
Only one pharmacist (other than the RP) was asked to 
carry out more than one consultation and although they 
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agreed, this is not enough to signify acceptability at this 
stage.
Potential to benefit clinical care
As in other studies the most common DRP identified was 
pain and several participants were not taking simple painkill-
ers as recommended because they had not been prescribed 
[11, 17]. The next most identified DRP was constipation, 
again a finding in other studies [16, 17, 20]. Almost three 
quarters of DRPs concerned treatment effectiveness. Sev-
enteen MRPs related to patients not understanding how and 
why to take medications after they had been prescribed. 
In some cases, medication was ineffective, and the patient 
required a stronger dose or a change in treatment.
Pharmacists were able to resolve the majority of DRPs 
with the patient; eight of the 19 patients were referred to 
nurses or GPs. Many of the referrals would have been pre-
vented if the pharmacist conducting the consultations had 
been a prescriber with access to medical records. In several 
previous studies, the pharmacist was either a trained pre-
scriber or was part of a palliative care team that could organ-
ise changes in prescribing [17–20, 39]. Acceptance of DRP 
recommendations by prescribers was unknown and future 
studies need to track this.
Limitations of the study
Most patients taking part already had access to palliative 
care professionals and associated medicines support. If 
patients had been recruited before referral to palliative care, 
there may have been an opportunity to educate at an earlier 
stage.
Patients receiving two consultations were hospice outpa-
tients who had already been referred to palliative care and 
therefore are more likely to have greater need for symptom 
control; this may have affected the type and number of DRPs 
found compared with those who had not been referred. It 
may be that this group would have more DRPs than those 
not yet referred to palliative care or it may be that they would 
have already had more opportunity to get DRPs addressed. 
This would benefit from further testing across both patient 
groups.
Acceptability was measured before, during and after the 
consultations. The numbers of participants, pharmacists 
and healthcare professionals returning questionnaires was 
small and this may affect the validity of the results.
Conclusion
The consultations were feasible to deliver, and patients 
found them acceptable. Community pharmacists were 
willing to provide these services although found working 
knowledge to be problematic due to the infrequent nature 
of the consultations. Further evaluation of clinical and 
cost-effectiveness is now needed.
Pharmacist medicines consultations were able to 
identify a substantial number of DRPs in patients with 
advanced cancer pain. Problems with inadequate pain 
relief and associated side effects were most prevalent and 
the majority of these could be addressed by the pharma-
cist even in patients already receiving specialist palliative 
care.
Acknowledgements The authors would like to acknowledge the role 
of Dr Liz Breen who acted as mentor for the author.
Funding The study was funded as part of the Improving the Manage-
ment of Pain from Advanced Cancer in the CommuniTy (IMPACCT) 
study which was a National Institute of Health Research pro-
gramme Grant of which this was part of the Medicines work stream 
(RP-PG-0610-10114).
Conflicts of interest The authors declared no potential conflicts of in-
terest with respect to this research and publication.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution 4.0 International License (http://creat iveco 
mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribu-
tion, and reproduction in any medium, provided you give appropriate 
credit to the original author(s) and the source, provide a link to the 
Creative Commons license, and indicate if changes were made.
Appendix 1
See Table 4.
708 International Journal of Clinical Pharmacy (2019) 41:700–710
1 3
Table 4  PCNE classification scheme for drug-related problems V8.02 [21]
Primary domain Code Problem
The problems
 1. Treatment effectiveness P1.1 No effect of drug treatment
P1.2 Effect of drug treatment not optimal
P1.3 Untreated symptoms or indication
 2. Treatment safety P2.1 Adverse drug event (possibly) occurring
 3. Others P3.1 Problem with cost-effectiveness of the treatment
P3.2 Unnecessary drug-treatment
P3.2 Unclear problem/complaint
Primary domain Code Cause
The causes
 1. Drug selection C1.1 Inappropriate drug according to guidelines/formulary
C1.2 Inappropriate drug (contra-indicated)
C1.3 No indication for drug
C1.4 Inappropriate combination of drugs (inc. herbal)
C1.5 Inappropriate duplication of therapeutic group/active ingredient
C1.6 No drug treatment in spite of existing indication
C1.7 Too many drugs prescribed for this indication
 2. Drug form C2.1 In appropriate drug form (for this patient)
 3. Dose selection C3.1 Drug dose too low
C3.2 Drug dose too high
C3.3 Dosage regiment not frequent enough
C3.4 Dosage regiment too frequent
C3.5 Dose timing instructions wrong, unclear or missing
 4. Treatment duration C4.1 Duration of treatment too short
C4.2 Duration of treatment too long
 5. Dispensing C5.1 Prescribed drug not available
C5.2 Necessary information not provided
C5.3 Wrong drug. Strength or dosage advised (over the counter)
C5.4 Wrong drug or strength dispensed
 6. Drug use process C6.1 Inappropriate timing of administration and/or dosing intervals
C6.2 Drug under-administered
C6.3 Drug over-administered
C6.4 Drug not administered at all
C6.5 Wrong drug administered
C6.6 Drug administered via wrong route
 7. Patient related C7.1 Patient uses/takes less drug than prescribed or does not take the drug at all
C7.2 Patient uses/takes more drug than prescribed
C7.3 Patient abuses drug (unregulated overuse)
C7.4 Patient uses unnecessary drug
C7.5 Patient takes food that interacts
C7.6 Patient stores drug inappropriately
C7.7 Inappropriate tining or dosing intervals
C7.8 Patient administers/uses the drug in a wrong way
C7.9 Patient unable to use drug/form as directed
 8. Other C8.1 No or inappropriate outcome monitoring
C8.2 Other cause; specify
C8.3 No obvious cause
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